Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print August 6, 2008, doi:10.1212/01.wnl.0000323812.40708.1f)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000323812.40708.1fv1
71/12/896    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishihara-Paul, L.
Right arrow Articles by Farrer, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishihara-Paul, L.
Right arrow Articles by Farrer, M. J.
Received September 18, 2007
Accepted May 20, 2008

PINK1 mutations and parkinsonism

L. Ishihara-Paul PhD, M. M. Hulihan MPH, J. Kachergus BSc, R. Upmanyu MSc, L. Warren PhD, R. Amouri PhD, R. Elango PhD, R. K. Prinjha PhD, A. Soto BSc, M. Kefi MDmm, M. Zouari MD, S. B. Sassi MD, S. B. Yahmed MD, G. El Euch-Fayeche MD, P. M. Matthews MD, PhD, L. T. Middleton MD, R. A. Gibson PhD, F. Hentati MD, and M. J. Farrer PhD*

From Research and Development (L.I.-P., R.U., R.E., R.K.P., P.M.M., L.T.M., R.A.G.), GlaxoSmithKline Pharmaceuticals, Harlow, Greenford, Hammersmith, UK; Neurogenetics (M.M.H., J.K., A.S., M.J.F.), Department of Neuroscience, Mayo Clinic, Jacksonville, FL; Research and Development (L.W.), GlaxoSmithKline Pharmaceuticals, Research Triangle Park, NC; and Service de Neurologie (R.A., M.K., M.Z., S.B.S., G.E.E.-F., S.B.Y., F.H.), Institut National de Neurologie, La Rabta, Tunis, Tunisia.


* To whom correspondence should be addressed. E-mail: farrer.matthew{at}mayo.edu.

Background: PINK1 loss-of-function causes recessive, early-onset parkinsonism. In Tunisia there is a high rate of consanguineous marriage but PINK1 carrier frequency and disease prevalence have yet to be assessed.

Objectives: The frequency of PINK1 mutations in familial parkinsonism, community-based patients with idiopathic Parkinson disease (PD) (non-familial PD), and control subjects was determined. Demographic and clinical characteristics of individuals with PINK1 homozygous or heterozygous variants, or without PINK1 mutations, were compared.

Methods: A total of 92 kindreds (with 208 affected and 340 unaffected subjects), 240 nonfamilial PD, and 368 control participants were recruited from the Institut National de Neurologie, Tunis. Clinical examinations included Hoehn & Yahr, UPDRS, and Epworth scales. PINK1 sequencing and dosage analysis was performed in familial index patients, the variants identified screened in all subjects. Parkin and LRRK2 genes were also examined.

Results: Four PINK1 homozygous mutations, three novel (Q129X, Q129fsX157, G440E, and one previously reported; Q456X), segregate with parkinsonism in 46 individuals in 14 of 92 families (15%). Six of 240 patients with nonfamilial PD were found with either homozygous Q456X or Q129X (2.5%) substitutions. In patients with familial disease, PINK1 homozygotes were younger at disease onset (36 ± 12 years) than noncarriers (57 ± 15 years) and more often had an akinetic-rigid presentation at examination and slow progression.

Conclusions: Segregation of PINK1 mutations with parkinsonism within families, and frequency estimates within population controls, suggested only four PINK1 mutations were pathogenic. Several PINK1 sequence variants are potentially benign and there was no evidence that PINK1 heterozygosity increases susceptibility to idiopathic Parkinson disease.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.